jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

ANA Profile

Blood

8 parameters

image

Report in 12Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Extended panel of antinuclear antibodies.

₹8,499₹12,450

32% OFF

Parameters

  • List of Tests
    • Anti Nuclear Antibodies (ANA)
    • Anti Ds_DNA
    • MPO-ANCA (P-ANCA)
    • PR3 - ANCA (C-ANCA)
    • Anti-ro SSA Antibodies by Immunoblot
    • Anti-la SSB Antibodies by Immunoblot
    • Anti-J0-1 Antibodies by Immunoblot
    • Anti-SM Antibodies by Immunoblot

ANA Profile

  • Why is it done?
    • The ANA Profile is a comprehensive autoimmune screening panel designed to detect and identify autoantibodies associated with systemic autoimmune diseases
    • Anti-Nuclear Antibodies (ANA): Primary screening test for systemic lupus erythematosus (SLE), scleroderma, and other connective tissue diseases; detects autoimmune activity targeting nuclear antigens
    • Anti-Ds-DNA: Specific marker for SLE diagnosis and disease activity monitoring; highly specific for systemic lupus erythematosus
    • MPO-ANCA (P-ANCA): Detects perinuclear Anti-Neutrophil Cytoplasmic Antibodies; aids in diagnosis of microscopic polyangiitis, granulomatosis with polyangiitis, and other vasculitides
    • PR3-ANCA (C-ANCA): Detects cytoplasmic Anti-Neutrophil Cytoplasmic Antibodies; primarily associated with granulomatosis with polyangiitis (formerly Wegener's granulomatosis)
    • Anti-Ro SSA Antibodies: Marker for Sjögren's syndrome, neonatal lupus, and SLE; associated with systemic manifestations and photosensitivity
    • Anti-La SSB Antibodies: Specific marker for primary Sjögren's syndrome; almost always occurs with Anti-Ro SSA positivity
    • Anti-Jo-1 Antibodies: Marker for idiopathic inflammatory myositis and myositis-associated autoimmune disease; associated with polymyositis and dermatomyositis
    • Anti-SM Antibodies: Highly specific marker for SLE; rarely present in other autoimmune conditions; excellent diagnostic specificity with 99%
    • Ordered when patients present with symptoms suggestive of autoimmune disease including arthritis, lupus-like rash, photosensitivity, dry mouth/eyes, muscle weakness, or unexplained systemic inflammation
    • Tests work synergistically to provide pattern recognition allowing differentiation between various autoimmune diseases and establishing definitive diagnosis
  • Normal Range
    • Anti-Nuclear Antibodies (ANA): Negative or titer <1:80; Positive results require follow-up with reflex to specific antibody testing
    • Anti-Ds-DNA: Negative (<0.9 IU/mL) or <5 IU/mL depending on laboratory; values below this threshold indicate normal immune response
    • MPO-ANCA (P-ANCA): Negative (<1.0 unit/mL); Normal result indicates absence of perinuclear ANCA antibodies
    • PR3-ANCA (C-ANCA): Negative (<1.0 unit/mL); Normal result indicates absence of cytoplasmic ANCA antibodies
    • Anti-Ro SSA Antibodies: Negative (< 0.1 Index or <1.0 IU/mL); Normal results indicate no detectable anti-Ro autoimmunity
    • Anti-La SSB Antibodies: Negative (< 0.1 Index or <1.0 IU/mL); Normal results indicate no detectable anti-La autoimmunity
    • Anti-Jo-1 Antibodies: Negative (< 0.1 Index or <1.0 IU/mL); Normal results indicate no detectable anti-Jo-1 antibodies
    • Anti-SM Antibodies: Negative (< 0.1 Index or <1.0 IU/mL); Normal results indicate no detectable anti-Smith autoimmunity
    • Borderline results (typically 0.1-1.0 Index) may warrant repeat testing or clinical correlation; normality varies by specific laboratory reagents and methodology
  • Interpretation
    • Anti-Nuclear Antibodies (ANA) Positive: Suggests autoimmune disease but not diagnostic alone; requires clinical symptoms and additional specific antibody testing for definitive diagnosis; approximately 3-5% of healthy population shows low-titer positive results
    • Anti-Ds-DNA Elevated (>0.9 IU/mL or >5 IU/mL): Highly specific for SLE diagnosis; levels often correlate with disease activity and lupus nephritis development; considered one of SLE classification criteria
    • MPO-ANCA Positive (>1.0 unit/mL): Associated with microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and other primary systemic vasculitides; pattern indicates possible pulmonary or renal involvement
    • PR3-ANCA Positive (>1.0 unit/mL): Highly specific for granulomatosis with polyangiitis; associated with upper respiratory tract, lower respiratory tract, and glomerulonephritis manifestations
    • Anti-Ro SSA Positive (>0.1 Index or >1.0 IU/mL): Consistent with Sjögren's syndrome, SLE, or neonatal lupus; indicates risk of photosensitive skin disease and cardiac conduction abnormalities if pregnant
    • Anti-La SSB Positive (>0.1 Index or >1.0 IU/mL): Highly specific for primary Sjögren's syndrome; virtually always occurs concurrently with Anti-Ro SSA; rarely occurs in isolation; indicates significant risk of systemic manifestations
    • Anti-Jo-1 Positive (>0.1 Index or >1.0 IU/mL): Indicates myositis-associated autoimmune disease; associated with polymyositis, dermatomyositis, and interstitial lung disease; frequently accompanied by other myositis antibodies
    • Anti-SM Positive (>0.1 Index or >1.0 IU/mL): Highly specific for SLE with 99% specificity; present in only 20-30% of SLE patients but virtually diagnostic when detected; used as SLE classification criterion
    • Multiple antibody positivity patterns help distinguish between autoimmune diseases; for example, Anti-Ro and Anti-La together strongly suggest Sjögren's while Anti-Ds-DNA and Anti-SM suggest SLE
    • Clinical correlation essential: Antibody positivity alone is insufficient for diagnosis; patient symptoms, physical examination findings, and laboratory results must support diagnosis
    • False positives may occur with infections (particularly viral), medications, malignancy, or other inflammatory conditions; repeat testing may be warranted for confirmation
  • Associated Organs
    • Anti-Nuclear Antibodies (ANA): Associated with multiple organ systems including kidneys (lupus nephritis), heart (pericarditis, myocarditis), lungs (pleuritis, pulmonary hemorrhage), skin (photosensitive rash, discoid lesions), and central nervous system
    • Anti-Ds-DNA: Primarily associated with kidney involvement; strong correlation with lupus nephritis development and renal disease progression; also associated with CNS lupus manifestations
    • MPO-ANCA: Associated with lung involvement (alveolar hemorrhage, pulmonary infiltrates), kidneys (glomerulonephritis, crescentic GN), and skin vasculitis; primary concern is end-stage renal disease development
    • PR3-ANCA: Associated with triad of upper respiratory tract (sinusitis, nasal crusting), lower respiratory tract (pulmonary infiltrates, hemoptysis), and kidneys (rapidly progressive glomerulonephritis); can affect heart with myocarditis
    • Anti-Ro SSA: Associated with exocrine glands (salivary gland dysfunction), eyes (dry eye syndrome), lungs (interstitial lung disease), heart (congenital heart block), and skin (photosensitivity, rash)
    • Anti-La SSB: Associated primarily with exocrine glands (salivary, lacrimal), skin (xerosis), lungs (interstitial fibrosis), kidneys (interstitial nephritis, glomerulonephritis), and nervous system (peripheral neuropathy)
    • Anti-Jo-1: Associated with skeletal muscle (myositis, muscle weakness), lungs (interstitial lung disease, pulmonary fibrosis), hands (Raynaud's phenomenon, mechanic's hands), and heart (cardiomyopathy, arrhythmias)
    • Anti-SM: Associated with kidneys (lupus nephritis), heart (pericarditis, endocarditis), lungs (pleuritis, pulmonary hemorrhage), and joints (arthritis); helps define systemic lupus erythematosus organ involvement
    • Potential complications from abnormal results include renal failure (from nephritis or GN), pulmonary hypertension, organ fibrosis, vasculitic crisis, neurological complications, and cardiac arrhythmias
  • Follow-up Tests
    • For positive ANA results: Consider ANA reflex panel with specific antibodies (already included in this comprehensive profile); additional imaging such as chest X-ray, high-resolution CT chest if pulmonary involvement suspected
    • For elevated Anti-Ds-DNA: Order urinalysis with microscopy, urine protein quantification, and serum creatinine to assess for lupus nephritis; assess C3 and C4 complement levels; baseline renal function essential
    • For positive ANCA results (MPO or PR3): Obtain baseline serum creatinine, urinalysis, and urine protein; consider chest imaging; renal biopsy may be indicated if rapidly progressive GN suspected
    • For positive Anti-Ro SSA: Evaluate for systemic involvement with chest imaging, pulmonary function tests if indicated; assess for cardiac arrhythmias with ECG; consider ophthalmology referral for Sjögren's evaluation
    • For positive Anti-La SSB: Refer to rheumatology and ENT; perform Schirmer's test and Rose Bengal staining for keratoconjunctivitis sicca confirmation; assess renal function with creatinine and urinalysis
    • For positive Anti-Jo-1: Order muscle enzyme testing (CK, aldolase, LDH, transaminases); perform EMG/NCS if myositis suspected; obtain pulmonary function tests and high-resolution CT chest to assess for ILD
    • For positive Anti-SM: Strongly suggests SLE requiring complete SLE workup including CBC, comprehensive metabolic panel, urinalysis, chest X-ray; assess for lupus nephritis with renal function tests
    • General follow-up monitoring frequency: Repeat ANA panel every 6-12 months for stable disease; more frequently (every 3 months) if disease activity suspected; correlate antibody titers with clinical symptoms
    • Complementary tests to consider: ESR and CRP for inflammation assessment; CBC for cytopenias; comprehensive metabolic panel for organ function; LFTs for hepatic involvement; coagulation studies if thrombosis risk
    • Consider comprehensive metabolic panel and CBC in all positive cases to assess overall systemic involvement and organ dysfunction
  • Fasting Required?
    • Fasting is NOT required for the ANA Profile or any of its individual component tests
    • Patients may eat and drink normally before specimen collection; no dietary restrictions apply to this serological panel
    • No specific medications need to be withheld; immunosuppressive therapy should continue as prescribed and does not interfere with accurate antibody detection
    • Specimen collection: Blood draw via venipuncture using standard serum separator or EDTA tube depending on laboratory protocol; typically 5-7 mL of blood required
    • Patient preparation: Arrive for blood draw during regular business hours; inform phlebotomist of any bleeding disorders or medications affecting coagulation
    • No need for special preparation or timing; specimen processing time typically 24-48 hours depending on laboratory; stat processing may be available if clinically urgent
    • Recommend scheduling appointment at patient convenience; multiple tests not recommended on same day unless medically necessary to avoid unnecessary blood draws

How our test process works!

customers
customers